AU2022423987A1 - Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof - Google Patents
Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof Download PDFInfo
- Publication number
- AU2022423987A1 AU2022423987A1 AU2022423987A AU2022423987A AU2022423987A1 AU 2022423987 A1 AU2022423987 A1 AU 2022423987A1 AU 2022423987 A AU2022423987 A AU 2022423987A AU 2022423987 A AU2022423987 A AU 2022423987A AU 2022423987 A1 AU2022423987 A1 AU 2022423987A1
- Authority
- AU
- Australia
- Prior art keywords
- cell
- seq
- ipsc
- domain
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
- A61K2239/13—Antibody-based
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163294618P | 2021-12-29 | 2021-12-29 | |
| US63/294,618 | 2021-12-29 | ||
| US202263350156P | 2022-06-08 | 2022-06-08 | |
| US63/350,156 | 2022-06-08 | ||
| PCT/US2022/082441 WO2023129937A1 (en) | 2021-12-29 | 2022-12-27 | Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022423987A1 true AU2022423987A1 (en) | 2024-07-11 |
Family
ID=85222536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022423987A Pending AU2022423987A1 (en) | 2021-12-29 | 2022-12-27 | Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250064934A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4456912A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025501214A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022423987A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3243966A1 (cg-RX-API-DMAC10.html) |
| TW (1) | TW202342734A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023129937A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250090582A1 (en) * | 2022-06-08 | 2025-03-20 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof |
| CN120435498A (zh) * | 2022-11-10 | 2025-08-05 | 世纪治疗股份有限公司 | 具有抗-nectin4嵌合抗原受体的基因工程化细胞及其用途 |
| WO2025207795A1 (en) * | 2024-03-26 | 2025-10-02 | Juno Therapeutics, Inc. | Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof |
| WO2025207798A1 (en) * | 2024-03-26 | 2025-10-02 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof |
| WO2025214438A1 (zh) * | 2024-04-10 | 2025-10-16 | 浙江纳米抗体技术中心有限公司 | 结合cd19和/或cd22的抗原结合分子及其用途 |
| CN121537531B (zh) * | 2026-01-16 | 2026-07-21 | 北京肿瘤医院(北京大学肿瘤医院) | 一种表达cd47-cd28共刺激转换受体的嵌合抗原受体及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
| US20040224385A1 (en) | 2001-08-20 | 2004-11-11 | Barbas Carlos F | Zinc finger binding domains for cnn |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8846395B2 (en) | 2005-06-01 | 2014-09-30 | Wisconsin Alumni Research Foundation | Generation of mature myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD43+CD45+progenitors |
| KR100902340B1 (ko) | 2007-08-02 | 2009-06-12 | 한국생명공학연구원 | Yc-1 또는 il-21을 유효성분으로 포함하는자연살해세포 분화제 및 분화 방법 |
| ES2587395T3 (es) | 2008-06-04 | 2016-10-24 | Cellular Dynamics International, Inc. | Procedimientos para la producción de células IPS usando un enfoque no vírico |
| JP5652783B2 (ja) | 2008-09-08 | 2015-01-14 | 独立行政法人理化学研究所 | NKT細胞由来iPS細胞およびそれ由来のNKT細胞 |
| CA2753679C (en) | 2009-02-27 | 2021-03-02 | Cellular Dynamics International, Inc. | Differentiation of pluripotent cells |
| PT2816112T (pt) | 2009-12-10 | 2018-11-20 | Univ Iowa State Res Found Inc | Modificação do adn modificada pelo efector tal |
| EP2601289B1 (en) | 2010-08-04 | 2017-07-12 | Cellular Dynamics International, Inc. | Reprogramming immortalized b cells |
| WO2012109208A2 (en) | 2011-02-08 | 2012-08-16 | Cellular Dynamics International, Inc. | Hematopoietic precursor cell production by programming |
| AU2015290554A1 (en) | 2014-07-18 | 2017-03-09 | Kyoto University | Method for inducing T cells for cell-based immunotherapy from pluripotent stem cells |
| WO2017070333A1 (en) | 2015-10-20 | 2017-04-27 | Cellular Dynamics International, Inc. | Multi-lineage hematopoietic precursor cell production by genetic programming |
| LT3444334T (lt) | 2016-04-15 | 2021-12-10 | Kyoto University | Antigenui specifinių cd8 teigiamų t ląstelių indikavimo būdas |
| JP7215994B2 (ja) | 2016-09-06 | 2023-01-31 | ザ チルドレンズ メディカル センター コーポレーション | 人工多能性幹細胞由来の免疫細胞 |
| KR102397771B1 (ko) | 2016-09-23 | 2022-05-13 | 프레드 헛친슨 켄서 리서치 센터 | 부 조직적합성(h) 항원 ha-1에 대해서 특이적인 tcr 및 이의 용도 |
| TW201908335A (zh) | 2017-07-25 | 2019-03-01 | 美國德州系統大學評議委員會 | 增強之嵌合抗原受體及其用途 |
| EP3684816B1 (en) | 2017-09-22 | 2024-05-29 | Kite Pharma, Inc. | Chimeric polypeptides and uses thereof |
| EP3692057B9 (en) | 2017-10-03 | 2023-10-04 | Precision BioSciences, Inc. | Modified epidermal growth factor receptor peptides for use in genetically-modified cells |
| CA3091158A1 (en) | 2018-02-14 | 2019-08-22 | Sunnybrook Research Institute | Method for generating cells of the t cell lineage |
| WO2020069184A2 (en) * | 2018-09-26 | 2020-04-02 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy |
| EP4041759A4 (en) * | 2019-10-07 | 2023-12-20 | Fate Therapeutics, Inc. | IMPROVED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTIVE CELL ENGINEERING AND ITS USE |
| WO2021092252A1 (en) * | 2019-11-05 | 2021-05-14 | Forman Stephen J | Generation of chimeric antigen receptor modified t cells from stem cells and therapeutic uses thereof |
| JP7805928B2 (ja) * | 2019-11-26 | 2026-01-26 | ノバルティス アーゲー | Cd19及びcd22キメラ抗原受容体及びその使用 |
| WO2021188599A1 (en) * | 2020-03-16 | 2021-09-23 | University Of Southern California | Novel antigen binding domains and synthetic antigen receptors incorporating the same |
| KR20230040337A (ko) * | 2020-06-19 | 2023-03-22 | 페이트 세러퓨틱스, 인코포레이티드 | 면역요법 사용을 위한 iPSC-유래 이펙터 세포 유형들의 조합 |
| TW202241935A (zh) * | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
-
2022
- 2022-12-27 WO PCT/US2022/082441 patent/WO2023129937A1/en not_active Ceased
- 2022-12-27 EP EP22856960.4A patent/EP4456912A1/en active Pending
- 2022-12-27 JP JP2024539426A patent/JP2025501214A/ja active Pending
- 2022-12-27 AU AU2022423987A patent/AU2022423987A1/en active Pending
- 2022-12-27 US US18/722,839 patent/US20250064934A1/en active Pending
- 2022-12-27 CA CA3243966A patent/CA3243966A1/en active Pending
- 2022-12-29 TW TW111150534A patent/TW202342734A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250064934A1 (en) | 2025-02-27 |
| EP4456912A1 (en) | 2024-11-06 |
| WO2023129937A1 (en) | 2023-07-06 |
| CA3243966A1 (en) | 2023-07-06 |
| TW202342734A (zh) | 2023-11-01 |
| JP2025501214A (ja) | 2025-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12269888B2 (en) | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof | |
| US20250064934A1 (en) | Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof | |
| US20240390496A1 (en) | Single-chain and multi-chain synthetic antigen receptors for diverse immune cells | |
| CA3214473A1 (en) | Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells | |
| US20220184123A1 (en) | Genetically Engineered Cells and Uses Thereof | |
| WO2025106626A1 (en) | Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof | |
| US20220331361A1 (en) | Gene transfer vectors and methods of engineering cells | |
| US20220195396A1 (en) | Genetically Engineered Cells and Uses Thereof | |
| US20250360210A1 (en) | Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof | |
| US20250090582A1 (en) | Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof | |
| US20250345425A1 (en) | Cells engineered with an hla-e and hla-g transgene | |
| US20230381317A1 (en) | Methods for controlled activation and/or expansion of genetically engineered cells using polyethylene glycol (peg) receptors | |
| US11661459B2 (en) | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof | |
| WO2025207798A1 (en) | Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof | |
| WO2025207795A1 (en) | Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof | |
| CN118742319A (zh) | 具有抗cd19/抗cd22嵌合抗原受体的基因工程化细胞及其用途 | |
| HK40117036A (en) | Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof | |
| AU2023375625A1 (en) | Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof |